Telratolimod

Telratolimod

CAT N°: 33172
Price:

From 182.00 154.70

Telratolimod is an agonist of toll-like receptor 7 (TLR7) and TLR8.{59921} It increases the production of IL-8 in HEK293 cells expressing human TLR7 or TLR8 and increases protein levels of IFN-? and TNF-? in isolated human peripheral blood mononuclear cells (PBMCs). Telratolimod (1 mg/kg) increases the HA-induced secretion of IFN-? in mouse splenocytes ex vivo but does not induce the production of TNF-? in mouse serum in vivo. Telratolimod nanoparticles, when used as an adjuvant with the HIV-1 envelope glycoprotein, enhance neutralizing antibody responses to an HIV-1 pseudovirus in rhesus macaques for at least one year.{59922} Intratumoral administration of telratolimod reduces tumor growth and increases metastasis-free survival in E0771 and 4T1.2 murine mammary carcinoma models and increases intratumoral production of cytokines in a 4T1.2 murine model, an effect that is enhanced by coadministration of anti-PD-1 antibodies.{59923}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-[(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy]butyl]-octadecanamide
  • Correlated keywords
    • TLR IL8 HEK-293 IFN? TFN? IFN? HIV1 pseudo-virus intra-tumoral co-administration PD1 3M052 MEDI 9197
  • Product Overview:
    Telratolimod is an agonist of toll-like receptor 7 (TLR7) and TLR8.{59921} It increases the production of IL-8 in HEK293 cells expressing human TLR7 or TLR8 and increases protein levels of IFN-? and TNF-? in isolated human peripheral blood mononuclear cells (PBMCs). Telratolimod (1 mg/kg) increases the HA-induced secretion of IFN-? in mouse splenocytes ex vivo but does not induce the production of TNF-? in mouse serum in vivo. Telratolimod nanoparticles, when used as an adjuvant with the HIV-1 envelope glycoprotein, enhance neutralizing antibody responses to an HIV-1 pseudovirus in rhesus macaques for at least one year.{59922} Intratumoral administration of telratolimod reduces tumor growth and increases metastasis-free survival in E0771 and 4T1.2 murine mammary carcinoma models and increases intratumoral production of cytokines in a 4T1.2 murine model, an effect that is enhanced by coadministration of anti-PD-1 antibodies.{59923}

We also advise you